

# Jonathan W Said

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2142876/publications.pdf>

Version: 2024-02-01

91  
papers

4,248  
citations

147801

31  
h-index

128289

60  
g-index

91  
all docs

91  
docs citations

91  
times ranked

5548  
citing authors

#	ARTICLE	IF	CITATIONS
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	7.2	1,023
2	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	1.4	401
3	Localization of Kaposi's Sarcoma-associated Herpesvirus in Bone Marrow Biopsy Samples From Patients With Multiple Myeloma. <i>Blood</i> , 1997, 90, 4278-4282.	1.4	153
4	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. <i>Journal of Experimental Medicine</i> , 2017, 214, 1371-1386.	8.5	144
5	HIV DNA Is Frequently Present within Pathologic Tissues Evaluated at Autopsy from Combined Antiretroviral Therapy-Treated Patients with Undetectable Viral Loads. <i>Journal of Virology</i> , 2016, 90, 8968-8983.	3.4	127
6	Mutations in the mitotic check point gene, MAD1L1, in human cancers. <i>Oncogene</i> , 2001, 20, 3301-3305.	5.9	108
7	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2170-2175.	7.1	102
8	Interleukin 2 Gene Therapy for Prostate Cancer: Phase I Clinical Trial and Basic Biology. <i>Human Gene Therapy</i> , 2001, 12, 883-892.	2.7	97
9	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	1.4	97
10	Synergistic effect of $\text{JQ-1}$ and rapamycin for treatment of human osteosarcoma. <i>International Journal of Cancer</i> , 2015, 136, 2055-2064.	5.1	95
11	Genomic landscape of liposarcoma. <i>Oncotarget</i> , 2015, 6, 42429-42444.	1.8	94
12	TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines. <i>Gastroenterology</i> , 2020, 159, 1311-1327.e19.	1.3	92
13	Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. <i>Blood</i> , 2018, 132, 1871-1878.	1.4	85
14	Circadian clock cryptochrome proteins regulate autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 12548-12553.	7.1	84
15	Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>European Urology</i> , 2017, 71, 766-773.	1.9	83
16	PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. , 2000, 42, 163-171.		74
17	Master transcription factors form interconnected circuitry and orchestrate transcriptional networks in oesophageal adenocarcinoma. <i>Gut</i> , 2020, 69, 630-640.	12.1	68
18	SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway. <i>Journal of Pathology</i> , 2015, 235, 559-570.	4.5	64

#	ARTICLE	IF	CITATIONS
19	BCL6 promotes glioma and serves as a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3981-3986.	7.1	58
20	Effect of Dietary Omega-3 Fatty Acids on Tumor-Associated Macrophages and Prostate Cancer Progression. Prostate, 2016, 76, 1293-1302.	2.3	51
21	Methylation of the p16INK4 gene in multiple myeloma. British Journal of Haematology, 1998, 101, 558-564.	2.5	50
22	Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma. Cancer Research, 2015, 75, 1815-1827.	0.9	50
23	Ultrastructural characterization of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) in Kaposi's sarcoma lesions: electron microscopy permits distinction from cytomegalovirus (CMV)., 1997, 182, 273-281.		48
24	Aggressive B-cell lymphomas: how many categories do we need?. Modern Pathology, 2013, 26, S42-S56.	5.5	47
25	Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate, 1999, 40, 141-149.	2.3	46
26	Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma. Clinical Cancer Research, 2017, 23, 4376-4387.	7.0	46
27	Immunodeficiency-related Hodgkin Lymphoma and its Mimics. Advances in Anatomic Pathology, 2007, 14, 189-194.	4.3	42
28	RNA-Binding Protein <i>ZFP36L1</i> Suppresses Hypoxia and Cell-Cycle Signaling. Cancer Research, 2020, 80, 219-233.	0.9	40
29	Is Kaposi's Sarcoma-Associated Herpesvirus Ubiquitous in Urogenital and Prostate Tissues?. Blood, 1997, 89, 1686-1689.	1.4	39
30	Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma. Nature Communications, 2019, 10, 1353.	12.8	39
31	Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget, 2017, 8, 7521-7532.	1.8	37
32	Establishing <sup>177</sup> Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1786-1792.	5.0	35
33	Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Scientific Reports, 2017, 7, 9749.	3.3	32
34	SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. Oncogene, 2019, 38, 6196-6210.	5.9	32
35	Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. Urology, 2017, 99, 270-277.	1.0	31
36	Biomarker discovery in urogenital cancer. Biomarkers, 2005, 10, 83-86.	1.9	29

#	ARTICLE	IF	CITATIONS
37	Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 204.e25-204.e33.	1.6	29
38	CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling. <i>Cancer Research</i> , 2016, 76, 2687-2697.	0.9	29
39	A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. <i>Journal of Urology</i> , 2018, 200, 564-572.	0.4	28
40	The MYC-BMI1 axis is essential for SETDB1-mediated breast tumorigenesis. <i>Journal of Pathology</i> , 2018, 246, 89-102.	4.5	28
41	Analysis of the CHK2 Gene in Lymphoid Malignancies. <i>Leukemia and Lymphoma</i> , 2001, 42, 517-520.	1.3	27
42	Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. <i>Journal of Hematology and Oncology</i> , 2017, 10, 173.	17.0	25
43	Microsatellite instability in adult T-cell leukaemia. <i>British Journal of Haematology</i> , 1998, 101, 341-344.	2.5	24
44	Phase II prospective randomized trial of weight loss prior to radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 212-220.	3.9	24
45	Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1326-1332.	2.5	22
46	Analysis of p18INK4C in adult T-cell leukaemia and non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1997, 99, 668-670.	2.5	21
47	Clinical characteristics and outcomes of PTLD following intestinal transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13313.	1.6	21
48	LNK suppresses interferon signaling in melanoma. <i>Nature Communications</i> , 2019, 10, 2230.	12.8	21
49	A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 563-572.	7.1	20
50	The expanding spectrum of EBV+ lymphomas. <i>Blood</i> , 2015, 126, 827-828.	1.4	19
51	Diffuse Aggressive B-cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2009, 16, 216-235.	4.3	18
52	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	1.9	18
53	Burkitt Lymphoma and MYC. <i>Advances in Anatomic Pathology</i> , 2014, 21, 160-165.	4.3	16
54	HIV, pathology and epigenetic age acceleration in different human tissues. <i>GeroScience</i> , 2022, 44, 1609-1620.	4.6	15

#	ARTICLE	IF	CITATIONS
55	B-lymphoblastic transformation of mantle cell lymphoma/leukemia with "double hit" changes. Journal of Hematopathology, 2015, 8, 31-36.	0.4	11
56	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. International Journal of Radiation Oncology Biology Physics, 2018, 101, 883-888.	0.8	10
57	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. American Journal of Surgical Pathology, 2021, 45, 384-393.	3.7	10
58	LPS independent activation of the pro-inflammatory receptor Trem1 by C/EBP $\beta$ in granulocytes. Scientific Reports, 2017, 7, 46440.	3.3	9
59	Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2018, 59, 321-329.	1.3	7
60	Mechanisms of Growth Control of Kaposi's Sarcoma-Associated Herpes Virus-Associated Primary Effusion Lymphoma Cells. Blood, 1998, 91, 2475-2481.	1.4	7
61	CD19/CD20 bispecific chimeric antigen receptor (CAR) in na $\beta$ ve/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2022, 40, 2543-2543.	1.6	6
62	Active Combination Therapy of Bortezomib (Velcade) and Ibritumomab Tiuxetan (Zevalin) in an In Vivo Diffuse Large B-Cell Lymphoma Model.. Blood, 2005, 106, 2406-2406.	1.4	5
63	CD70 is a promising CAR-T cell target in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2022, 40, 384-384.	1.6	4
64	Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. Urology, 2017, 107, 171-177.	1.0	3
65	Multicentric Castleman disease: consensus at last?. Blood, 2017, 129, 1569-1570.	1.4	3
66	Ascorbic Acid Overcomes Drug Resistance in Myeloma and Significantly Increases the Anti-Myeloma Effects of both Arsenic Trioxide and Melphalan in Vitro and in Vivo.. Blood, 2004, 104, 2470-2470.	1.4	3
67	Bortezomib Is a Novel Inducer of Latent Epstein Barr Virus (EBV) in EBV+ Lymphoma Cell Lines.. Blood, 2006, 108, 2511-2511.	1.4	3
68	Arsenic Trioxide Shows Synergistic Anti-Myeloma Effects When Combined with Bortezomib and Melphalan In Vitro and Helps Overcome Resistance of Multiple Myeloma Cells to These Treatments in Vivo.. Blood, 2004, 104, 2467-2467.	1.4	3
69	Severe mosquito bite allergy: an unusual EBV+ NK cell lymphoproliferative disorder. Blood, 2019, 133, 999-999.	1.4	2
70	Trisomy 3, a sole recurrent cytogenetic abnormality in pediatric polymorphic post-transplant lymphoproliferative disorder (PTLD). Cancer Genetics, 2020, 248-249, 39-48.	0.4	2
71	Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance. Blood, 2015, 126, 1029-1029.	1.4	2
72	Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401). Blood, 2015, 126, 334-334.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Clinical and pathological diagnosis of peripheral T-cell lymphoma and emerging treatment options: A case-based discussion. <i>Clinical Advances in Hematology and Oncology</i> , 2009, 7, S1, S4-13; quiz S15.	0.3	2
74	Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. , 1999, 40, 141.		1
75	PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. <i>Prostate</i> , 2000, 42, 163.	2.3	1
76	Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study. <i>Blood</i> , 2008, 112, 476-476.	1.4	1
77	Blocking Pleiotrophin Activity Inhibits Multiple Myeloma (MM) Cell Growth In Vitro and in a Severe Combined Immunodeficient (SCID)-hu Murine Model of Human MM.. <i>Blood</i> , 2005, 106, 114-114.	1.4	1
78	Expression of Circadian Core Clock Gene Per2 Is Markedly Down-Regulated in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 4470-4470.	1.4	1
79	A phase I, open-label, dose-escalation and cohort expansion study evaluating the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 653-653.	1.6	1
80	Coexpression of cytokeratin and B cell markersâ€”a rare finding with new implications. <i>Journal of Hematopathology</i> , 2015, 8, 95-97.	0.4	0
81	Analysis of YY1 and XIAP Expression, Proteins That Regulate Resistance, in AIDS-NHL Tissue Arrays.. <i>Blood</i> , 2005, 106, 1933-1933.	1.4	0
82	Spectrum of Expression and Biological Activity of Programmed Death Ligand 1 (PD-L1) in Non-Hodgkinâ€™s Lymphomas. <i>Blood</i> , 2008, 112, 4140-4140.	1.4	0
83	CEBPalpha and a Critical Circadian Clock Downstream Target Gene, PER2, Are Highly Dysregulated in Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3454-3454.	1.4	0
84	Certification and role of local pathologists for diffuse large B-cell lymphoma (DLBCL) subtyping and eligibility determination in the phase II PYRAMID study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8559-8559.	1.6	0
85	Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance.. <i>Journal of Clinical Oncology</i> , 2014, 32, 93-93.	1.6	0
86	Validation of the CAIX score as a prognostic biomarker for lymphatic spread and cancer-specific survival.. <i>Journal of Clinical Oncology</i> , 2014, 32, 454-454.	1.6	0
87	The role of obesity in the incidence of lymphatic spread, disease-free, and overall survival: Data from the ARISER clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 435-435.	1.6	0
88	C/EBPÎµ Plays a Role in Immunity By Regulating Trem-1 Expression in Granulocytes. <i>Blood</i> , 2014, 124, 4100-4100.	1.4	0
89	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 509-509.	1.6	0
90	Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era.. <i>Journal of Clinical Oncology</i> , 2017, 2017, 7-7.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era.. Journal of Clinical Oncology, 2017, 35, 7-7.	1.6	0